Cargando…

Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells

Thymoquinone, a therapeutic phytochemical derived from Nigella sativa, has been shown to have a potent anticancer activity. However, it has been identified that the tumor microenvironment (TME) can attenuate the anticancer effects of thymoquinone (TQ) in ovarian cancer. Lysophosphatidic acid (LPA),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ha, Ji Hee, Jayaraman, Muralidharan, Radhakrishnan, Rangasudhagar, Gomathinayagam, Rohini, Yan, Mingda, Song, Yong Sang, Isidoro, Ciro, Dhanasekaran, Danny N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Ovarian cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340879/ https://www.ncbi.nlm.nih.gov/pubmed/32670815 http://dx.doi.org/10.1016/j.jtcme.2020.04.001

Ejemplares similares

Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved
por: Vallino, Letizia, et al.
Publicado: (2020)

Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
por: Gomathinayagam, Rohini, et al.
Publicado: (2020)

Determinant role for the gep oncogenes, Gα12/13, in ovarian cancer cell proliferation and xenograft tumor growth
por: Ha, Ji Hee, et al.
Publicado: (2015)

Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Gαi2, Src, and HIF1α signaling nexus
por: Ha, Ji Hee, et al.
Publicado: (2016)

Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis
por: Gunderson, Camille C, et al.
Publicado: (2022)

Cellular Senescence in the Treatment of Ovarian Cancer
por: Wang, Zehua, et al.
Publicado: (2018)

Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015)

GNAi2/gip2-Regulated Transcriptome and Its Therapeutic Significance in Ovarian Cancer
por: Ha, Ji Hee, et al.
Publicado: (2021)

Identification of GNA12-driven gene signatures and key signaling networks in ovarian cancer
por: Ha, Ji-Hee, et al.
Publicado: (2021)

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017)

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism
por: Sakurai, Manabu, et al.
Publicado: (2017)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer
por: Kleppe, Marjolein, et al.
Publicado: (2015)

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a “Molecular Second Look”
por: Schwartz, Melissa, et al.
Publicado: (2018)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Wang, Haihong, et al.
Publicado: (2018)

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers
por: Sölétormos, György, et al.
Publicado: (2016)

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario
por: McGee, Jacob, et al.
Publicado: (2017)

Hax-1 is required for Rac1-Cortactin interaction and ovarian carcinoma cell migration
por: Gomathinayagam, Rohini, et al.
Publicado: (2014)

High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension
por: Sakurai, Manabu, et al.
Publicado: (2015)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2015)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
por: Oza, Amit M., et al.
Publicado: (2017)

Short-term Outcomes and Pregnancy Rate After Laparoscopic Fertility-Sparing Surgery for Borderline Ovarian Tumors: A Single-Institute Experience
por: Zhao, Jianguo, et al.
Publicado: (2018)

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
por: Leiserowitz, Gary S., et al.
Publicado: (2017)

Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer
por: Ha, Ji Hee, et al.
Publicado: (2016)

Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center
por: Alwazzan, Ahmad Bakr, et al.
Publicado: (2015)

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2018)

Recent advances in systemic treatments for ovarian cancer
por: Banerjee, Susana, et al.
Publicado: (2012)

Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer
por: Jayaraman, Muralidharan, et al.
Publicado: (2017)

New ways of assessing ovarian cancer response: metabolic imaging and beyond
por: Rockall, Andrea, et al.
Publicado: (2012)

Unraveling Autocrine Signaling Pathways through Metabolic Fingerprinting in Serous Ovarian Cancer Cells
por: Ha, Ji Hee, et al.
Publicado: (2021)

Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies
por: Nadhan, Revathy, et al.
Publicado: (2023)

Updates on fluorescent probes and open‐field imaging methods for fluorescence‐guided cytoreductive surgery for epithelial ovarian cancer: A review
por: Sun, Chongen, et al.
Publicado: (2022)

High co‐expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer
por: Wu, Xiaodong, et al.
Publicado: (2022)

A radiomic nomogram based on arterial phase of CT for differential diagnosis of ovarian cancer
por: Hu, Yumin, et al.
Publicado: (2021)

The second annual conference of International ovarian cancer consortium and the symposium on tumor microenvironment and therapeutic resistance
por: Isidoro, Ciro, et al.
Publicado: (2016)

Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
por: Pandey, Avinash, et al.
Publicado: (2016)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uvultpmmgn3mbbpgsglalbk9q7